Quidel to Present at the 37th Annual Canaccord Genuity Growth Conference
July 31 2017 - 4:10PM
Business Wire
Quidel Corporation (NASDAQ: QDEL), a provider of rapid
diagnostic testing solutions, cellular-based virology assays and
molecular diagnostic systems, announced today that it will present
at the 37th Annual Canaccord Genuity Growth Conference, to be held
at the InterContinental Boston hotel in Boston, Massachusetts on
Wednesday, August 9, 2017.
Douglas Bryant, president and chief executive officer, and Randy
Steward, chief financial officer, will present that day at 11:30
a.m. Eastern time (8:30 a.m. Pacific time) with a question and
answer session scheduled immediately following the presentation.
During the presentation, the company will discuss business and
financial developments and trends. The company's statements may
contain or constitute material information that has not been
previously disclosed.
A live webcast and audio archive of each presentation will be
available via the Investor Relations section of the company’s Web
site at http://ir.quidel.com or by clicking on the following
link:
http://wsw.com/webcast/canaccord26/qdel
Participants should allow approximately five to ten minutes
prior to the presentation's start time to visit the site and
download any streaming media software needed to listen to the
Internet webcast. A replay of the webcast will also be available on
the company’s Web site for 14 days.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well-being
of people around the globe through the development of diagnostic
solutions that can lead to improved patient outcomes and provide
economic benefits to the healthcare system. Marketed under the
Sofia®, QuickVue®, D3® Direct Detection, Thyretain® and
InflammaDry® leading brand names, as well as under the new Solana®,
AmpliVue® and Lyra® molecular diagnostic brands, Quidel's products
aid in the detection and diagnosis of many critical diseases and
conditions, including, among others, influenza, respiratory
syncytial virus, Strep A, herpes, pregnancy, thyroid disease and
fecal occult blood. Quidel's research and development engine is
also developing a continuum of diagnostic solutions from advanced
lateral-flow and direct fluorescent antibody to molecular
diagnostic tests to further improve the quality of healthcare in
physicians' offices and hospital and reference laboratories. For
more information about Quidel's comprehensive product portfolio,
visit quidel.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170731006088/en/
Quidel Contact:Quidel CorporationRandy StewardChief Financial
Officer(858) 552-7931orMedia and Investors Contact:Quidel
CorporationRuben Argueta(858) 646-8023rargueta@quidel.com
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Apr 2023 to Apr 2024